BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9625129)

  • 1. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
    Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
    Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
    Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
    Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
    Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
    Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
    Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
    Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
    Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
    Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
    Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
    Afify A; Lynne LC; Howell L
    Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of CD44v6 amplification for the detection of tumour cells in the blood of colorectal cancer patients.
    Masson D; Denis MG; Lustenberger P
    Br J Cancer; 2000 Apr; 82(7):1283-9. PubMed ID: 10755402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
    Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
    Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD44v6 has no prognostic value in patients with colorectal cancer.
    Jüngling B; Menges M; Goebel R; Wittig BM; Weg-Remers S; Pistorius G; Schilling M; Bauer M; König J; Zeitz M; Stallmach A
    Z Gastroenterol; 2002 Apr; 40(4):229-33. PubMed ID: 11961731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
    Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
    Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
    Gadducci A; Ferdeghini M; Cosio S; Annicchiarico C; Fanucchi A; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1998; 18(1B):537-9. PubMed ID: 9568174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Fanucchi A; Annicchiarico C; Cosio S; Prontera C; Bianchi R; Genazzani AR
    Anticancer Res; 1997; 17(6D):4463-6. PubMed ID: 9494551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
    Chang SM; Xing RD; Zhang FM; Duan YQ
    Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
    Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
    Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
    Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
    Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance.
    Nguyen VN; Mirejovský T; Melinová L; Mandys V
    Neoplasma; 2000; 47(6):400-8. PubMed ID: 11263866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer.
    Zlobec I; Günthert U; Tornillo L; Iezzi G; Baumhoer D; Terracciano L; Lugli A
    Histopathology; 2009 Nov; 55(5):564-75. PubMed ID: 19912362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
    Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
    Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer.
    Masson D; Denis MG; Denis M; Blanchard D; Loirat MJ; Cassagnau E; Lustenberger P
    Br J Cancer; 1999 Aug; 80(12):1995-2000. PubMed ID: 10471052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.